Attached files
| file | filename |
|---|---|
| 8-K/A - AMENDMENT TO FORM 8-K - Nuo Therapeutics, Inc. | v306796_8ka.htm |
| EX-99.2 - EXHIBIT 99.2 - Nuo Therapeutics, Inc. | v306796_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - Nuo Therapeutics, Inc. | v306796_ex99-1.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Post-Effective Amendment No. 5 to Form S-8 (No. 333-162135) pertaining to the Cytomedix, Inc. Long-Term Incentive Plan of Cytomedix, Inc., |
| (2) | Post-Effective Amendment No. 2 to Form S-1 (No. 333-170747) and related Prospectus of Cytomedix, Inc. for the registration of 12,336,538 shares of its common stock, |
| (3) | Post-Effective Amendment No. 2 to Form S-3 on Form S-1 (No. 333- 147793) and related Prospectus of Cytomedix, Inc. for the registration of 5,001,924 shares of its common stock, and |
| (4) | Post-Effective Amendment No. 2 to Form S-3 on Form S-1 (S-1 No. 333- 168936) and related Prospectus of Cytomedix, Inc. for the registration of 7,841,496 shares of its common stock; |
of our report dated March 13, 2012, with respect to the financial statements of Aldagen, Inc. included in this Amendment No. 1 to Current Report on Form 8-K dated February 8, 2012 on Form 8-K/A of Cytomedix, Inc. dated March 29, 2012.
| /s/ Ernst & Young LLP |
Raleigh, North Carolina
March 29, 2012